News about "Merck"

Merck's Capvaxive Shows Strong Phase 3 Results in Children and Adolescents at High Risk of Pneumococcal Disease

Merck, known as MSD outside the United States and Canada, has reported positive results from its Phase 3 STRIDE-13 trial evaluating Capvaxive, its 21-valent pneumococcal conjugate vaccine.

Merck | 12/09/2025 | By Darshana

Merck Shuts Down London Drug Discovery Centre, Moves R&D Focus to US

Merck has announced that it will discontinue its drug discovery operations in London, citing an increasingly challenging business environment in the UK. The company has abandoned plans to occupy the Belgrove House site at King’s Cross—which had been scheduled to open in 2027—and will relocate research activities primarily to existing sites in the USA.

Merck | 12/09/2025 | By Darshana

Merck, BMS, Pfizer to Be Hit Hard by Looming Patent Cliff: Report Warns

Major pharmaceutical players, including Merck, Bristol Myers Squibb (BMS), Johnson and Johnson, Pfizer, and Novartis, are expected to experience significant revenue losses as several of their blockbuster drugs approach patent expirations, according to a new report by Research and Markets.

Merck | 28/07/2025 | By Dineshwori |  175

Merck to Acquire Verona Pharma for USD 10 Billion to Expand Cardio-Pulmonary Portfolio

Merck, through a subsidiary, will acquire Verona Pharma for USD 107 per American Depository Share (ADS), each of which represents eight shares of Verona Pharma, for a total transaction value of approximately USD 10 billion.

Merck | 10/07/2025 | By Dineshwori |  192

Merck Signs Exclusive License Deal for HRS-5346 with Hengrui Pharma

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

Merck | 26/03/2025 | By Aishwarya |  254

Merck Signs Exclusive Global License Deal with Hansoh Pharma for Oral GLP-1 Receptor Agonist

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535.

Merck | 19/12/2024 | By Aishwarya |  366

Merck Signs MoU with Siemens to Accelerate Digital Transformation Technology

The MoU makes Siemens a preferred global supplier and strategic partner for Smartfacturing technologies, paving the way for transformative projects across Merck's three business sectors.

Merck | 18/09/2024 | By Aishwarya |  462

Merck to Acquire CN201 from Curon Biopharmaceutical

CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for treating patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.

Merck | 14/08/2024 | By Aishwarya |  255

Merck Acquires Mirus Bio to Advance Viral Vector Bioprocessing

Merck has completed the acquisition of Mirus Bio for approximately USD 600 million (around EUR 550 million), following regulatory clearances and the fulfillment of other customary closing conditions.

Merck | 03/08/2024 | By Aishwarya |  483

Merck Signs MoU with Gene Therapy Research Institution

Merck has signed a non-binding Memorandum of Understanding (MoU) with Gene Therapy Research Institution Co., Ltd. (GTRI), a Japanese clinical-stage biotech start-up specializing in gene therapy using adeno-associated virus (AAV) vectors.

Merck | 25/07/2024 | By Aishwarya |  490